3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Metabolic responses in blood-stage malaria parasites associated with increased and decreased sensitivity to PfATP4 inhibitors

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Spiroindolone and pyrazoleamide antimalarial compounds target Plasmodium falciparum P-type ATPase (PfATP4) and induce disruption of intracellular Na + homeostasis. Recently, a PfATP4 mutation was discovered that confers resistance to a pyrazoleamide while increasing sensitivity to a spiroindolone. Transcriptomic and metabolic adaptations that underlie this seemingly contradictory response of P. falciparum to sublethal concentrations of each compound were examined to understand the different cellular accommodation to PfATP4 disruptions.

          Methods

          A genetically engineered P. falciparum Dd2 strain (Dd2 A211V) carrying an Ala211Val (A211V) mutation in PfATP4 was used to identify metabolic adaptations associated with the mutation that results in decreased sensitivity to PA21A092 (a pyrazoleamide) and increased sensitivity to KAE609 (a spiroindolone). First, sublethal doses of PA21A092 and KAE609 causing substantial reduction (30–70%) in Dd2 A211V parasite replication were identified. Then, at this sublethal dose of PA21A092 (or KAE609), metabolomic and transcriptomic data were collected during the first intraerythrocytic developmental cycle. Finally, the time-resolved data were integrated with a whole-genome metabolic network model of P. falciparum to characterize antimalarial-induced physiological adaptations.

          Results

          Sublethal treatment with PA21A092 caused significant ( p < 0.001) alterations in the abundances of 91 Plasmodium gene transcripts, whereas only 21 transcripts were significantly altered due to sublethal treatment with KAE609. In the metabolomic data, a substantial alteration (≥ fourfold) in the abundances of carbohydrate metabolites in the presence of either compound was found. The estimated rates of macromolecule syntheses between the two antimalarial-treated conditions were also comparable, except for the rate of lipid synthesis. A closer examination of parasite metabolism in the presence of either compound indicated statistically significant differences in enzymatic activities associated with synthesis of phosphatidylcholine, phosphatidylserine, and phosphatidylinositol.

          Conclusion

          The results of this study suggest that malaria parasites activate protein kinases via phospholipid-dependent signalling in response to the ionic perturbation induced by the Na + homeostasis disruptor PA21A092. Therefore, targeted disruption of phospholipid signalling in PA21A092-resistant parasites could be a means to block the emergence of resistance to PA21A092.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12936-023-04481-x.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: not found
          • Article: not found

          The control of the false discovery rate in multiple testing under dependency

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            AKT/PKB signaling: navigating downstream.

            The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli. Aberrant loss or gain of Akt activation underlies the pathophysiological properties of a variety of complex diseases, including type-2 diabetes and cancer. Here, we review the molecular properties of Akt and the approaches used to characterize its true cellular targets. In addition, we discuss those Akt substrates that are most likely to contribute to the diverse cellular roles of Akt, which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Spiroindolones, a potent compound class for the treatment of malaria.

              Recent reports of increased tolerance to artemisinin derivatives--the most recently adopted class of antimalarials--have prompted a need for new treatments. The spirotetrahydro-beta-carbolines, or spiroindolones, are potent drugs that kill the blood stages of Plasmodium falciparum and Plasmodium vivax clinical isolates at low nanomolar concentration. Spiroindolones rapidly inhibit protein synthesis in P. falciparum, an effect that is ablated in parasites bearing nonsynonymous mutations in the gene encoding the P-type cation-transporter ATPase4 (PfATP4). The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model.
                Bookmark

                Author and article information

                Contributors
                stewari@bhsai.org
                sven.a.wallqvist.civ@health.mil
                Journal
                Malar J
                Malar J
                Malaria Journal
                BioMed Central (London )
                1475-2875
                14 February 2023
                14 February 2023
                2023
                : 22
                : 56
                Affiliations
                [1 ]GRID grid.420210.5, ISNI 0000 0001 0036 4726, Department of Defense Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, , U.S. Army Medical Research and Development Command, ; Fort Detrick, MD USA
                [2 ]GRID grid.201075.1, ISNI 0000 0004 0614 9826, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., ; Bethesda, MD USA
                [3 ]GRID grid.21107.35, ISNI 0000 0001 2171 9311, Department of Molecular Microbiology and Immunology, , Johns Hopkins University, ; Baltimore, MD USA
                [4 ]GRID grid.166341.7, ISNI 0000 0001 2181 3113, Center for Molecular Parasitology, Department of Microbiology and Immunology, , Drexel University College of Medicine, ; Philadelphia, PA USA
                [5 ]GRID grid.417587.8, ISNI 0000 0001 2243 3366, Present Address: Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, , U.S. Food and Drug Administration, ; Silver Spring, MD USA
                Article
                4481
                10.1186/s12936-023-04481-x
                9930341
                36788578
                a4f14b5a-321b-4482-8805-87ffed38fb4c
                © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 2 December 2022
                : 3 February 2023
                Funding
                Funded by: U.S. Army Medical Research and Development Command
                Award ID: W81XWH-14-2-0134
                Award ID: W81XWH-15-C-0061
                Award Recipient :
                Funded by: National Institutes of Health Grant
                Award ID: R01 AI125534
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2023

                Infectious disease & Microbiology
                drug resistance,genome-scale metabolic network model,metabolomics,na+ homeostasis,plasmodium falciparum,transcriptomics

                Comments

                Comment on this article